• Profile
Close

Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies

Respiratory Medicine Jul 25, 2019

Tashkin DP, et al. - Researchers evaluated how the efficacy and safety of indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 μg twice daily vs its monocomponents or placebo is influenced by smoking status in patients with COPD in this post hoc examination of pooled data from the replicate, 12-week, placebo-controlled FLIGHT1 and FLIGHT2 studies. They pooled baseline data from 2,038 patients and defined categories by smoking status (52% were current smokers and 48% were ex-smokers). Significant improvements in lung function and patient-reported outcomes (PROs) were reported in relation to treatment with IND/GLY, and this occurred independently of baseline smoking status. With IND/GLY vs its monocomponents, greater improvements in lung function and PROs were reported in current and ex-smokers. No difference was found with regard to the safety profile of IND/GLY between current and ex-smokers.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay